ml218  (Alomone Labs)


Bioz Verified Symbol Alomone Labs is a verified supplier
Bioz Manufacturer Symbol Alomone Labs manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 92

    Structured Review

    Alomone Labs ml218
    Effects of asenapine on cytosolic Ca 2+ in H9C2 in the presence or absence of serotoninergic and dopaminergic receptor blockers and L- and T-type Ca 2+ channels inhibitors. An example of each experimental protocol is shown. (a) 2 min asenapine (A) with 5-HT 1A inhibitor, NAD-299 (NAD); (b) with L type Ca 2+ channel blocker, amlodipine (Amlod); (c) with T type Ca 2+ channel blocker, <t>ML218;</t> (d) with D2 receptor inhibitor, propionyl promazine (Propionyl); (e) with 5-HT 2A inhibitor, nefazodone (Nefaz). The layout is the same as in Figure 3
    Ml218, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ml218/product/Alomone Labs
    Average 92 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    ml218 - by Bioz Stars, 2021-12
    92/100 stars

    Images

    1) Product Images from "Asenapine modulates nitric oxide release and calcium movements in cardiomyoblasts"

    Article Title: Asenapine modulates nitric oxide release and calcium movements in cardiomyoblasts

    Journal: Journal of Pharmacology & Pharmacotherapeutics

    doi: 10.4103/0976-500X.179358

    Effects of asenapine on cytosolic Ca 2+ in H9C2 in the presence or absence of serotoninergic and dopaminergic receptor blockers and L- and T-type Ca 2+ channels inhibitors. An example of each experimental protocol is shown. (a) 2 min asenapine (A) with 5-HT 1A inhibitor, NAD-299 (NAD); (b) with L type Ca 2+ channel blocker, amlodipine (Amlod); (c) with T type Ca 2+ channel blocker, ML218; (d) with D2 receptor inhibitor, propionyl promazine (Propionyl); (e) with 5-HT 2A inhibitor, nefazodone (Nefaz). The layout is the same as in Figure 3
    Figure Legend Snippet: Effects of asenapine on cytosolic Ca 2+ in H9C2 in the presence or absence of serotoninergic and dopaminergic receptor blockers and L- and T-type Ca 2+ channels inhibitors. An example of each experimental protocol is shown. (a) 2 min asenapine (A) with 5-HT 1A inhibitor, NAD-299 (NAD); (b) with L type Ca 2+ channel blocker, amlodipine (Amlod); (c) with T type Ca 2+ channel blocker, ML218; (d) with D2 receptor inhibitor, propionyl promazine (Propionyl); (e) with 5-HT 2A inhibitor, nefazodone (Nefaz). The layout is the same as in Figure 3

    Techniques Used:

    Effects of asenapine on cytosolic Ca 2+ in H9C2 in peroxidative conditions. (a) Dose-response and time-course study. The results are the mean ± standard deviation of five experiments. (b) An example taken from one experiment. (c) Effects of asenapine on Ca 2+ in the presence or absence of various blockers. C = Basal; A = Asenapine; Nefaz = Nefazodone (1 μM); propionyl = Propionyl promazine (1 μM); NAD = NAD-299 (1 μM); amlodip = Amlodipine (1 μM); ML218 = ML218 (1 μM); L-NAME = Nω-nitro-L-arginine methyl ester (10 mM). The results are the mean ± standard deviation of five experiments for each experimental protocol. (c) b, d, e P
    Figure Legend Snippet: Effects of asenapine on cytosolic Ca 2+ in H9C2 in peroxidative conditions. (a) Dose-response and time-course study. The results are the mean ± standard deviation of five experiments. (b) An example taken from one experiment. (c) Effects of asenapine on Ca 2+ in the presence or absence of various blockers. C = Basal; A = Asenapine; Nefaz = Nefazodone (1 μM); propionyl = Propionyl promazine (1 μM); NAD = NAD-299 (1 μM); amlodip = Amlodipine (1 μM); ML218 = ML218 (1 μM); L-NAME = Nω-nitro-L-arginine methyl ester (10 mM). The results are the mean ± standard deviation of five experiments for each experimental protocol. (c) b, d, e P

    Techniques Used: Standard Deviation

    Effects of asenapine on nitric oxide release in H9C2. (a) Dose-response and time-course study. (b) Effects of 15 min asenapine (10 pM-100 μM) in peroxidative conditions. (c) Effects of 2 min asenapine (100 nM) in the presence or absence of various agents. A = Asenapine; amlodip = Amlodipine (1 μM); NAD = NAD-299 (1 μM); Nefaz = Nefazodone (1 μM); propionyl = Propionyl promazine (1 μM); ML218 = ML218 (1 μM); 2'5' =2'5' dideoxyadenosine (1 μM): H89 = H89 (1 μM); KN93 = KN93 (1 μM); U73 = U73122 (1 μM); L-NAME = Nω-nitro-L-arginine methyl ester (10 mM). Nitric oxide release is expressed as % in comparison to basal values (c). The results are the mean ± standard deviation of five experiments for each experimental protocol. (c) b, c, e, g, i, m, o, q, s, u, z P
    Figure Legend Snippet: Effects of asenapine on nitric oxide release in H9C2. (a) Dose-response and time-course study. (b) Effects of 15 min asenapine (10 pM-100 μM) in peroxidative conditions. (c) Effects of 2 min asenapine (100 nM) in the presence or absence of various agents. A = Asenapine; amlodip = Amlodipine (1 μM); NAD = NAD-299 (1 μM); Nefaz = Nefazodone (1 μM); propionyl = Propionyl promazine (1 μM); ML218 = ML218 (1 μM); 2'5' =2'5' dideoxyadenosine (1 μM): H89 = H89 (1 μM); KN93 = KN93 (1 μM); U73 = U73122 (1 μM); L-NAME = Nω-nitro-L-arginine methyl ester (10 mM). Nitric oxide release is expressed as % in comparison to basal values (c). The results are the mean ± standard deviation of five experiments for each experimental protocol. (c) b, c, e, g, i, m, o, q, s, u, z P

    Techniques Used: Standard Deviation

    2) Product Images from "Asenapine modulates nitric oxide release and calcium movements in cardiomyoblasts"

    Article Title: Asenapine modulates nitric oxide release and calcium movements in cardiomyoblasts

    Journal: Journal of Pharmacology & Pharmacotherapeutics

    doi: 10.4103/0976-500X.179358

    Effects of asenapine on cytosolic Ca 2+ in H9C2 in the presence or absence of serotoninergic and dopaminergic receptor blockers and L- and T-type Ca 2+ channels inhibitors. An example of each experimental protocol is shown. (a) 2 min asenapine (A) with 5-HT 1A inhibitor, NAD-299 (NAD); (b) with L type Ca 2+ channel blocker, amlodipine (Amlod); (c) with T type Ca 2+ channel blocker, ML218; (d) with D2 receptor inhibitor, propionyl promazine (Propionyl); (e) with 5-HT 2A inhibitor, nefazodone (Nefaz). The layout is the same as in Figure 3
    Figure Legend Snippet: Effects of asenapine on cytosolic Ca 2+ in H9C2 in the presence or absence of serotoninergic and dopaminergic receptor blockers and L- and T-type Ca 2+ channels inhibitors. An example of each experimental protocol is shown. (a) 2 min asenapine (A) with 5-HT 1A inhibitor, NAD-299 (NAD); (b) with L type Ca 2+ channel blocker, amlodipine (Amlod); (c) with T type Ca 2+ channel blocker, ML218; (d) with D2 receptor inhibitor, propionyl promazine (Propionyl); (e) with 5-HT 2A inhibitor, nefazodone (Nefaz). The layout is the same as in Figure 3

    Techniques Used:

    Effects of asenapine on cytosolic Ca 2+ in H9C2 in peroxidative conditions. (a) Dose-response and time-course study. The results are the mean ± standard deviation of five experiments. (b) An example taken from one experiment. (c) Effects of asenapine on Ca 2+ in the presence or absence of various blockers. C = Basal; A = Asenapine; Nefaz = Nefazodone (1 μM); propionyl = Propionyl promazine (1 μM); NAD = NAD-299 (1 μM); amlodip = Amlodipine (1 μM); ML218 = ML218 (1 μM); L-NAME = Nω-nitro-L-arginine methyl ester (10 mM). The results are the mean ± standard deviation of five experiments for each experimental protocol. (c) b, d, e P
    Figure Legend Snippet: Effects of asenapine on cytosolic Ca 2+ in H9C2 in peroxidative conditions. (a) Dose-response and time-course study. The results are the mean ± standard deviation of five experiments. (b) An example taken from one experiment. (c) Effects of asenapine on Ca 2+ in the presence or absence of various blockers. C = Basal; A = Asenapine; Nefaz = Nefazodone (1 μM); propionyl = Propionyl promazine (1 μM); NAD = NAD-299 (1 μM); amlodip = Amlodipine (1 μM); ML218 = ML218 (1 μM); L-NAME = Nω-nitro-L-arginine methyl ester (10 mM). The results are the mean ± standard deviation of five experiments for each experimental protocol. (c) b, d, e P

    Techniques Used: Standard Deviation

    Effects of asenapine on nitric oxide release in H9C2. (a) Dose-response and time-course study. (b) Effects of 15 min asenapine (10 pM-100 μM) in peroxidative conditions. (c) Effects of 2 min asenapine (100 nM) in the presence or absence of various agents. A = Asenapine; amlodip = Amlodipine (1 μM); NAD = NAD-299 (1 μM); Nefaz = Nefazodone (1 μM); propionyl = Propionyl promazine (1 μM); ML218 = ML218 (1 μM); 2'5' =2'5' dideoxyadenosine (1 μM): H89 = H89 (1 μM); KN93 = KN93 (1 μM); U73 = U73122 (1 μM); L-NAME = Nω-nitro-L-arginine methyl ester (10 mM). Nitric oxide release is expressed as % in comparison to basal values (c). The results are the mean ± standard deviation of five experiments for each experimental protocol. (c) b, c, e, g, i, m, o, q, s, u, z P
    Figure Legend Snippet: Effects of asenapine on nitric oxide release in H9C2. (a) Dose-response and time-course study. (b) Effects of 15 min asenapine (10 pM-100 μM) in peroxidative conditions. (c) Effects of 2 min asenapine (100 nM) in the presence or absence of various agents. A = Asenapine; amlodip = Amlodipine (1 μM); NAD = NAD-299 (1 μM); Nefaz = Nefazodone (1 μM); propionyl = Propionyl promazine (1 μM); ML218 = ML218 (1 μM); 2'5' =2'5' dideoxyadenosine (1 μM): H89 = H89 (1 μM); KN93 = KN93 (1 μM); U73 = U73122 (1 μM); L-NAME = Nω-nitro-L-arginine methyl ester (10 mM). Nitric oxide release is expressed as % in comparison to basal values (c). The results are the mean ± standard deviation of five experiments for each experimental protocol. (c) b, c, e, g, i, m, o, q, s, u, z P

    Techniques Used: Standard Deviation

    3) Product Images from "Asenapine modulates nitric oxide release and calcium movements in cardiomyoblasts"

    Article Title: Asenapine modulates nitric oxide release and calcium movements in cardiomyoblasts

    Journal: Journal of Pharmacology & Pharmacotherapeutics

    doi: 10.4103/0976-500X.179358

    Effects of asenapine on cytosolic Ca 2+ in H9C2 in the presence or absence of serotoninergic and dopaminergic receptor blockers and L- and T-type Ca 2+ channels inhibitors. An example of each experimental protocol is shown. (a) 2 min asenapine (A) with 5-HT 1A inhibitor, NAD-299 (NAD); (b) with L type Ca 2+ channel blocker, amlodipine (Amlod); (c) with T type Ca 2+ channel blocker, ML218; (d) with D2 receptor inhibitor, propionyl promazine (Propionyl); (e) with 5-HT 2A inhibitor, nefazodone (Nefaz). The layout is the same as in Figure 3
    Figure Legend Snippet: Effects of asenapine on cytosolic Ca 2+ in H9C2 in the presence or absence of serotoninergic and dopaminergic receptor blockers and L- and T-type Ca 2+ channels inhibitors. An example of each experimental protocol is shown. (a) 2 min asenapine (A) with 5-HT 1A inhibitor, NAD-299 (NAD); (b) with L type Ca 2+ channel blocker, amlodipine (Amlod); (c) with T type Ca 2+ channel blocker, ML218; (d) with D2 receptor inhibitor, propionyl promazine (Propionyl); (e) with 5-HT 2A inhibitor, nefazodone (Nefaz). The layout is the same as in Figure 3

    Techniques Used:

    Effects of asenapine on cytosolic Ca 2+ in H9C2 in peroxidative conditions. (a) Dose-response and time-course study. The results are the mean ± standard deviation of five experiments. (b) An example taken from one experiment. (c) Effects of asenapine on Ca 2+ in the presence or absence of various blockers. C = Basal; A = Asenapine; Nefaz = Nefazodone (1 μM); propionyl = Propionyl promazine (1 μM); NAD = NAD-299 (1 μM); amlodip = Amlodipine (1 μM); ML218 = ML218 (1 μM); L-NAME = Nω-nitro-L-arginine methyl ester (10 mM). The results are the mean ± standard deviation of five experiments for each experimental protocol. (c) b, d, e P
    Figure Legend Snippet: Effects of asenapine on cytosolic Ca 2+ in H9C2 in peroxidative conditions. (a) Dose-response and time-course study. The results are the mean ± standard deviation of five experiments. (b) An example taken from one experiment. (c) Effects of asenapine on Ca 2+ in the presence or absence of various blockers. C = Basal; A = Asenapine; Nefaz = Nefazodone (1 μM); propionyl = Propionyl promazine (1 μM); NAD = NAD-299 (1 μM); amlodip = Amlodipine (1 μM); ML218 = ML218 (1 μM); L-NAME = Nω-nitro-L-arginine methyl ester (10 mM). The results are the mean ± standard deviation of five experiments for each experimental protocol. (c) b, d, e P

    Techniques Used: Standard Deviation

    Effects of asenapine on nitric oxide release in H9C2. (a) Dose-response and time-course study. (b) Effects of 15 min asenapine (10 pM-100 μM) in peroxidative conditions. (c) Effects of 2 min asenapine (100 nM) in the presence or absence of various agents. A = Asenapine; amlodip = Amlodipine (1 μM); NAD = NAD-299 (1 μM); Nefaz = Nefazodone (1 μM); propionyl = Propionyl promazine (1 μM); ML218 = ML218 (1 μM); 2'5' =2'5' dideoxyadenosine (1 μM): H89 = H89 (1 μM); KN93 = KN93 (1 μM); U73 = U73122 (1 μM); L-NAME = Nω-nitro-L-arginine methyl ester (10 mM). Nitric oxide release is expressed as % in comparison to basal values (c). The results are the mean ± standard deviation of five experiments for each experimental protocol. (c) b, c, e, g, i, m, o, q, s, u, z P
    Figure Legend Snippet: Effects of asenapine on nitric oxide release in H9C2. (a) Dose-response and time-course study. (b) Effects of 15 min asenapine (10 pM-100 μM) in peroxidative conditions. (c) Effects of 2 min asenapine (100 nM) in the presence or absence of various agents. A = Asenapine; amlodip = Amlodipine (1 μM); NAD = NAD-299 (1 μM); Nefaz = Nefazodone (1 μM); propionyl = Propionyl promazine (1 μM); ML218 = ML218 (1 μM); 2'5' =2'5' dideoxyadenosine (1 μM): H89 = H89 (1 μM); KN93 = KN93 (1 μM); U73 = U73122 (1 μM); L-NAME = Nω-nitro-L-arginine methyl ester (10 mM). Nitric oxide release is expressed as % in comparison to basal values (c). The results are the mean ± standard deviation of five experiments for each experimental protocol. (c) b, c, e, g, i, m, o, q, s, u, z P

    Techniques Used: Standard Deviation

    4) Product Images from "Asenapine modulates nitric oxide release and calcium movements in cardiomyoblasts"

    Article Title: Asenapine modulates nitric oxide release and calcium movements in cardiomyoblasts

    Journal: Journal of Pharmacology & Pharmacotherapeutics

    doi: 10.4103/0976-500X.179358

    Effects of asenapine on cytosolic Ca 2+ in H9C2 in the presence or absence of serotoninergic and dopaminergic receptor blockers and L- and T-type Ca 2+ channels inhibitors. An example of each experimental protocol is shown. (a) 2 min asenapine (A) with 5-HT 1A inhibitor, NAD-299 (NAD); (b) with L type Ca 2+ channel blocker, amlodipine (Amlod); (c) with T type Ca 2+ channel blocker, ML218; (d) with D2 receptor inhibitor, propionyl promazine (Propionyl); (e) with 5-HT 2A inhibitor, nefazodone (Nefaz). The layout is the same as in Figure 3
    Figure Legend Snippet: Effects of asenapine on cytosolic Ca 2+ in H9C2 in the presence or absence of serotoninergic and dopaminergic receptor blockers and L- and T-type Ca 2+ channels inhibitors. An example of each experimental protocol is shown. (a) 2 min asenapine (A) with 5-HT 1A inhibitor, NAD-299 (NAD); (b) with L type Ca 2+ channel blocker, amlodipine (Amlod); (c) with T type Ca 2+ channel blocker, ML218; (d) with D2 receptor inhibitor, propionyl promazine (Propionyl); (e) with 5-HT 2A inhibitor, nefazodone (Nefaz). The layout is the same as in Figure 3

    Techniques Used:

    Effects of asenapine on cytosolic Ca 2+ in H9C2 in peroxidative conditions. (a) Dose-response and time-course study. The results are the mean ± standard deviation of five experiments. (b) An example taken from one experiment. (c) Effects of asenapine on Ca 2+ in the presence or absence of various blockers. C = Basal; A = Asenapine; Nefaz = Nefazodone (1 μM); propionyl = Propionyl promazine (1 μM); NAD = NAD-299 (1 μM); amlodip = Amlodipine (1 μM); ML218 = ML218 (1 μM); L-NAME = Nω-nitro-L-arginine methyl ester (10 mM). The results are the mean ± standard deviation of five experiments for each experimental protocol. (c) b, d, e P
    Figure Legend Snippet: Effects of asenapine on cytosolic Ca 2+ in H9C2 in peroxidative conditions. (a) Dose-response and time-course study. The results are the mean ± standard deviation of five experiments. (b) An example taken from one experiment. (c) Effects of asenapine on Ca 2+ in the presence or absence of various blockers. C = Basal; A = Asenapine; Nefaz = Nefazodone (1 μM); propionyl = Propionyl promazine (1 μM); NAD = NAD-299 (1 μM); amlodip = Amlodipine (1 μM); ML218 = ML218 (1 μM); L-NAME = Nω-nitro-L-arginine methyl ester (10 mM). The results are the mean ± standard deviation of five experiments for each experimental protocol. (c) b, d, e P

    Techniques Used: Standard Deviation

    Effects of asenapine on nitric oxide release in H9C2. (a) Dose-response and time-course study. (b) Effects of 15 min asenapine (10 pM-100 μM) in peroxidative conditions. (c) Effects of 2 min asenapine (100 nM) in the presence or absence of various agents. A = Asenapine; amlodip = Amlodipine (1 μM); NAD = NAD-299 (1 μM); Nefaz = Nefazodone (1 μM); propionyl = Propionyl promazine (1 μM); ML218 = ML218 (1 μM); 2'5' =2'5' dideoxyadenosine (1 μM): H89 = H89 (1 μM); KN93 = KN93 (1 μM); U73 = U73122 (1 μM); L-NAME = Nω-nitro-L-arginine methyl ester (10 mM). Nitric oxide release is expressed as % in comparison to basal values (c). The results are the mean ± standard deviation of five experiments for each experimental protocol. (c) b, c, e, g, i, m, o, q, s, u, z P
    Figure Legend Snippet: Effects of asenapine on nitric oxide release in H9C2. (a) Dose-response and time-course study. (b) Effects of 15 min asenapine (10 pM-100 μM) in peroxidative conditions. (c) Effects of 2 min asenapine (100 nM) in the presence or absence of various agents. A = Asenapine; amlodip = Amlodipine (1 μM); NAD = NAD-299 (1 μM); Nefaz = Nefazodone (1 μM); propionyl = Propionyl promazine (1 μM); ML218 = ML218 (1 μM); 2'5' =2'5' dideoxyadenosine (1 μM): H89 = H89 (1 μM); KN93 = KN93 (1 μM); U73 = U73122 (1 μM); L-NAME = Nω-nitro-L-arginine methyl ester (10 mM). Nitric oxide release is expressed as % in comparison to basal values (c). The results are the mean ± standard deviation of five experiments for each experimental protocol. (c) b, c, e, g, i, m, o, q, s, u, z P

    Techniques Used: Standard Deviation

    5) Product Images from "Asenapine modulates nitric oxide release and calcium movements in cardiomyoblasts"

    Article Title: Asenapine modulates nitric oxide release and calcium movements in cardiomyoblasts

    Journal: Journal of Pharmacology & Pharmacotherapeutics

    doi: 10.4103/0976-500X.179358

    Effects of asenapine on cytosolic Ca 2+ in H9C2 in the presence or absence of serotoninergic and dopaminergic receptor blockers and L- and T-type Ca 2+ channels inhibitors. An example of each experimental protocol is shown. (a) 2 min asenapine (A) with 5-HT 1A inhibitor, NAD-299 (NAD); (b) with L type Ca 2+ channel blocker, amlodipine (Amlod); (c) with T type Ca 2+ channel blocker, ML218; (d) with D2 receptor inhibitor, propionyl promazine (Propionyl); (e) with 5-HT 2A inhibitor, nefazodone (Nefaz). The layout is the same as in Figure 3
    Figure Legend Snippet: Effects of asenapine on cytosolic Ca 2+ in H9C2 in the presence or absence of serotoninergic and dopaminergic receptor blockers and L- and T-type Ca 2+ channels inhibitors. An example of each experimental protocol is shown. (a) 2 min asenapine (A) with 5-HT 1A inhibitor, NAD-299 (NAD); (b) with L type Ca 2+ channel blocker, amlodipine (Amlod); (c) with T type Ca 2+ channel blocker, ML218; (d) with D2 receptor inhibitor, propionyl promazine (Propionyl); (e) with 5-HT 2A inhibitor, nefazodone (Nefaz). The layout is the same as in Figure 3

    Techniques Used:

    Effects of asenapine on cytosolic Ca 2+ in H9C2 in peroxidative conditions. (a) Dose-response and time-course study. The results are the mean ± standard deviation of five experiments. (b) An example taken from one experiment. (c) Effects of asenapine on Ca 2+ in the presence or absence of various blockers. C = Basal; A = Asenapine; Nefaz = Nefazodone (1 μM); propionyl = Propionyl promazine (1 μM); NAD = NAD-299 (1 μM); amlodip = Amlodipine (1 μM); ML218 = ML218 (1 μM); L-NAME = Nω-nitro-L-arginine methyl ester (10 mM). The results are the mean ± standard deviation of five experiments for each experimental protocol. (c) b, d, e P
    Figure Legend Snippet: Effects of asenapine on cytosolic Ca 2+ in H9C2 in peroxidative conditions. (a) Dose-response and time-course study. The results are the mean ± standard deviation of five experiments. (b) An example taken from one experiment. (c) Effects of asenapine on Ca 2+ in the presence or absence of various blockers. C = Basal; A = Asenapine; Nefaz = Nefazodone (1 μM); propionyl = Propionyl promazine (1 μM); NAD = NAD-299 (1 μM); amlodip = Amlodipine (1 μM); ML218 = ML218 (1 μM); L-NAME = Nω-nitro-L-arginine methyl ester (10 mM). The results are the mean ± standard deviation of five experiments for each experimental protocol. (c) b, d, e P

    Techniques Used: Standard Deviation

    Effects of asenapine on nitric oxide release in H9C2. (a) Dose-response and time-course study. (b) Effects of 15 min asenapine (10 pM-100 μM) in peroxidative conditions. (c) Effects of 2 min asenapine (100 nM) in the presence or absence of various agents. A = Asenapine; amlodip = Amlodipine (1 μM); NAD = NAD-299 (1 μM); Nefaz = Nefazodone (1 μM); propionyl = Propionyl promazine (1 μM); ML218 = ML218 (1 μM); 2'5' =2'5' dideoxyadenosine (1 μM): H89 = H89 (1 μM); KN93 = KN93 (1 μM); U73 = U73122 (1 μM); L-NAME = Nω-nitro-L-arginine methyl ester (10 mM). Nitric oxide release is expressed as % in comparison to basal values (c). The results are the mean ± standard deviation of five experiments for each experimental protocol. (c) b, c, e, g, i, m, o, q, s, u, z P
    Figure Legend Snippet: Effects of asenapine on nitric oxide release in H9C2. (a) Dose-response and time-course study. (b) Effects of 15 min asenapine (10 pM-100 μM) in peroxidative conditions. (c) Effects of 2 min asenapine (100 nM) in the presence or absence of various agents. A = Asenapine; amlodip = Amlodipine (1 μM); NAD = NAD-299 (1 μM); Nefaz = Nefazodone (1 μM); propionyl = Propionyl promazine (1 μM); ML218 = ML218 (1 μM); 2'5' =2'5' dideoxyadenosine (1 μM): H89 = H89 (1 μM); KN93 = KN93 (1 μM); U73 = U73122 (1 μM); L-NAME = Nω-nitro-L-arginine methyl ester (10 mM). Nitric oxide release is expressed as % in comparison to basal values (c). The results are the mean ± standard deviation of five experiments for each experimental protocol. (c) b, c, e, g, i, m, o, q, s, u, z P

    Techniques Used: Standard Deviation

    6) Product Images from "Asenapine modulates nitric oxide release and calcium movements in cardiomyoblasts"

    Article Title: Asenapine modulates nitric oxide release and calcium movements in cardiomyoblasts

    Journal: Journal of Pharmacology & Pharmacotherapeutics

    doi: 10.4103/0976-500X.179358

    Effects of asenapine on cytosolic Ca 2+ in H9C2 in the presence or absence of serotoninergic and dopaminergic receptor blockers and L- and T-type Ca 2+ channels inhibitors. An example of each experimental protocol is shown. (a) 2 min asenapine (A) with 5-HT 1A inhibitor, NAD-299 (NAD); (b) with L type Ca 2+ channel blocker, amlodipine (Amlod); (c) with T type Ca 2+ channel blocker, ML218; (d) with D2 receptor inhibitor, propionyl promazine (Propionyl); (e) with 5-HT 2A inhibitor, nefazodone (Nefaz). The layout is the same as in Figure 3
    Figure Legend Snippet: Effects of asenapine on cytosolic Ca 2+ in H9C2 in the presence or absence of serotoninergic and dopaminergic receptor blockers and L- and T-type Ca 2+ channels inhibitors. An example of each experimental protocol is shown. (a) 2 min asenapine (A) with 5-HT 1A inhibitor, NAD-299 (NAD); (b) with L type Ca 2+ channel blocker, amlodipine (Amlod); (c) with T type Ca 2+ channel blocker, ML218; (d) with D2 receptor inhibitor, propionyl promazine (Propionyl); (e) with 5-HT 2A inhibitor, nefazodone (Nefaz). The layout is the same as in Figure 3

    Techniques Used:

    Effects of asenapine on cytosolic Ca 2+ in H9C2 in peroxidative conditions. (a) Dose-response and time-course study. The results are the mean ± standard deviation of five experiments. (b) An example taken from one experiment. (c) Effects of asenapine on Ca 2+ in the presence or absence of various blockers. C = Basal; A = Asenapine; Nefaz = Nefazodone (1 μM); propionyl = Propionyl promazine (1 μM); NAD = NAD-299 (1 μM); amlodip = Amlodipine (1 μM); ML218 = ML218 (1 μM); L-NAME = Nω-nitro-L-arginine methyl ester (10 mM). The results are the mean ± standard deviation of five experiments for each experimental protocol. (c) b, d, e P
    Figure Legend Snippet: Effects of asenapine on cytosolic Ca 2+ in H9C2 in peroxidative conditions. (a) Dose-response and time-course study. The results are the mean ± standard deviation of five experiments. (b) An example taken from one experiment. (c) Effects of asenapine on Ca 2+ in the presence or absence of various blockers. C = Basal; A = Asenapine; Nefaz = Nefazodone (1 μM); propionyl = Propionyl promazine (1 μM); NAD = NAD-299 (1 μM); amlodip = Amlodipine (1 μM); ML218 = ML218 (1 μM); L-NAME = Nω-nitro-L-arginine methyl ester (10 mM). The results are the mean ± standard deviation of five experiments for each experimental protocol. (c) b, d, e P

    Techniques Used: Standard Deviation

    Effects of asenapine on nitric oxide release in H9C2. (a) Dose-response and time-course study. (b) Effects of 15 min asenapine (10 pM-100 μM) in peroxidative conditions. (c) Effects of 2 min asenapine (100 nM) in the presence or absence of various agents. A = Asenapine; amlodip = Amlodipine (1 μM); NAD = NAD-299 (1 μM); Nefaz = Nefazodone (1 μM); propionyl = Propionyl promazine (1 μM); ML218 = ML218 (1 μM); 2'5' =2'5' dideoxyadenosine (1 μM): H89 = H89 (1 μM); KN93 = KN93 (1 μM); U73 = U73122 (1 μM); L-NAME = Nω-nitro-L-arginine methyl ester (10 mM). Nitric oxide release is expressed as % in comparison to basal values (c). The results are the mean ± standard deviation of five experiments for each experimental protocol. (c) b, c, e, g, i, m, o, q, s, u, z P
    Figure Legend Snippet: Effects of asenapine on nitric oxide release in H9C2. (a) Dose-response and time-course study. (b) Effects of 15 min asenapine (10 pM-100 μM) in peroxidative conditions. (c) Effects of 2 min asenapine (100 nM) in the presence or absence of various agents. A = Asenapine; amlodip = Amlodipine (1 μM); NAD = NAD-299 (1 μM); Nefaz = Nefazodone (1 μM); propionyl = Propionyl promazine (1 μM); ML218 = ML218 (1 μM); 2'5' =2'5' dideoxyadenosine (1 μM): H89 = H89 (1 μM); KN93 = KN93 (1 μM); U73 = U73122 (1 μM); L-NAME = Nω-nitro-L-arginine methyl ester (10 mM). Nitric oxide release is expressed as % in comparison to basal values (c). The results are the mean ± standard deviation of five experiments for each experimental protocol. (c) b, c, e, g, i, m, o, q, s, u, z P

    Techniques Used: Standard Deviation

    7) Product Images from "Asenapine modulates nitric oxide release and calcium movements in cardiomyoblasts"

    Article Title: Asenapine modulates nitric oxide release and calcium movements in cardiomyoblasts

    Journal: Journal of Pharmacology & Pharmacotherapeutics

    doi: 10.4103/0976-500X.179358

    Effects of asenapine on cytosolic Ca 2+ in H9C2 in the presence or absence of serotoninergic and dopaminergic receptor blockers and L- and T-type Ca 2+ channels inhibitors. An example of each experimental protocol is shown. (a) 2 min asenapine (A) with 5-HT 1A inhibitor, NAD-299 (NAD); (b) with L type Ca 2+ channel blocker, amlodipine (Amlod); (c) with T type Ca 2+ channel blocker, ML218; (d) with D2 receptor inhibitor, propionyl promazine (Propionyl); (e) with 5-HT 2A inhibitor, nefazodone (Nefaz). The layout is the same as in Figure 3
    Figure Legend Snippet: Effects of asenapine on cytosolic Ca 2+ in H9C2 in the presence or absence of serotoninergic and dopaminergic receptor blockers and L- and T-type Ca 2+ channels inhibitors. An example of each experimental protocol is shown. (a) 2 min asenapine (A) with 5-HT 1A inhibitor, NAD-299 (NAD); (b) with L type Ca 2+ channel blocker, amlodipine (Amlod); (c) with T type Ca 2+ channel blocker, ML218; (d) with D2 receptor inhibitor, propionyl promazine (Propionyl); (e) with 5-HT 2A inhibitor, nefazodone (Nefaz). The layout is the same as in Figure 3

    Techniques Used:

    Effects of asenapine on cytosolic Ca 2+ in H9C2 in peroxidative conditions. (a) Dose-response and time-course study. The results are the mean ± standard deviation of five experiments. (b) An example taken from one experiment. (c) Effects of asenapine on Ca 2+ in the presence or absence of various blockers. C = Basal; A = Asenapine; Nefaz = Nefazodone (1 μM); propionyl = Propionyl promazine (1 μM); NAD = NAD-299 (1 μM); amlodip = Amlodipine (1 μM); ML218 = ML218 (1 μM); L-NAME = Nω-nitro-L-arginine methyl ester (10 mM). The results are the mean ± standard deviation of five experiments for each experimental protocol. (c) b, d, e P
    Figure Legend Snippet: Effects of asenapine on cytosolic Ca 2+ in H9C2 in peroxidative conditions. (a) Dose-response and time-course study. The results are the mean ± standard deviation of five experiments. (b) An example taken from one experiment. (c) Effects of asenapine on Ca 2+ in the presence or absence of various blockers. C = Basal; A = Asenapine; Nefaz = Nefazodone (1 μM); propionyl = Propionyl promazine (1 μM); NAD = NAD-299 (1 μM); amlodip = Amlodipine (1 μM); ML218 = ML218 (1 μM); L-NAME = Nω-nitro-L-arginine methyl ester (10 mM). The results are the mean ± standard deviation of five experiments for each experimental protocol. (c) b, d, e P

    Techniques Used: Standard Deviation

    Effects of asenapine on nitric oxide release in H9C2. (a) Dose-response and time-course study. (b) Effects of 15 min asenapine (10 pM-100 μM) in peroxidative conditions. (c) Effects of 2 min asenapine (100 nM) in the presence or absence of various agents. A = Asenapine; amlodip = Amlodipine (1 μM); NAD = NAD-299 (1 μM); Nefaz = Nefazodone (1 μM); propionyl = Propionyl promazine (1 μM); ML218 = ML218 (1 μM); 2'5' =2'5' dideoxyadenosine (1 μM): H89 = H89 (1 μM); KN93 = KN93 (1 μM); U73 = U73122 (1 μM); L-NAME = Nω-nitro-L-arginine methyl ester (10 mM). Nitric oxide release is expressed as % in comparison to basal values (c). The results are the mean ± standard deviation of five experiments for each experimental protocol. (c) b, c, e, g, i, m, o, q, s, u, z P
    Figure Legend Snippet: Effects of asenapine on nitric oxide release in H9C2. (a) Dose-response and time-course study. (b) Effects of 15 min asenapine (10 pM-100 μM) in peroxidative conditions. (c) Effects of 2 min asenapine (100 nM) in the presence or absence of various agents. A = Asenapine; amlodip = Amlodipine (1 μM); NAD = NAD-299 (1 μM); Nefaz = Nefazodone (1 μM); propionyl = Propionyl promazine (1 μM); ML218 = ML218 (1 μM); 2'5' =2'5' dideoxyadenosine (1 μM): H89 = H89 (1 μM); KN93 = KN93 (1 μM); U73 = U73122 (1 μM); L-NAME = Nω-nitro-L-arginine methyl ester (10 mM). Nitric oxide release is expressed as % in comparison to basal values (c). The results are the mean ± standard deviation of five experiments for each experimental protocol. (c) b, c, e, g, i, m, o, q, s, u, z P

    Techniques Used: Standard Deviation

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 92
    Alomone Labs ml218
    Effects of asenapine on cytosolic Ca 2+ in H9C2 in the presence or absence of serotoninergic and dopaminergic receptor blockers and L- and T-type Ca 2+ channels inhibitors. An example of each experimental protocol is shown. (a) 2 min asenapine (A) with 5-HT 1A inhibitor, NAD-299 (NAD); (b) with L type Ca 2+ channel blocker, amlodipine (Amlod); (c) with T type Ca 2+ channel blocker, <t>ML218;</t> (d) with D2 receptor inhibitor, propionyl promazine (Propionyl); (e) with 5-HT 2A inhibitor, nefazodone (Nefaz). The layout is the same as in Figure 3
    Ml218, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ml218/product/Alomone Labs
    Average 92 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    ml218 - by Bioz Stars, 2021-12
    92/100 stars
      Buy from Supplier

    Image Search Results


    Effects of asenapine on cytosolic Ca 2+ in H9C2 in the presence or absence of serotoninergic and dopaminergic receptor blockers and L- and T-type Ca 2+ channels inhibitors. An example of each experimental protocol is shown. (a) 2 min asenapine (A) with 5-HT 1A inhibitor, NAD-299 (NAD); (b) with L type Ca 2+ channel blocker, amlodipine (Amlod); (c) with T type Ca 2+ channel blocker, ML218; (d) with D2 receptor inhibitor, propionyl promazine (Propionyl); (e) with 5-HT 2A inhibitor, nefazodone (Nefaz). The layout is the same as in Figure 3

    Journal: Journal of Pharmacology & Pharmacotherapeutics

    Article Title: Asenapine modulates nitric oxide release and calcium movements in cardiomyoblasts

    doi: 10.4103/0976-500X.179358

    Figure Lengend Snippet: Effects of asenapine on cytosolic Ca 2+ in H9C2 in the presence or absence of serotoninergic and dopaminergic receptor blockers and L- and T-type Ca 2+ channels inhibitors. An example of each experimental protocol is shown. (a) 2 min asenapine (A) with 5-HT 1A inhibitor, NAD-299 (NAD); (b) with L type Ca 2+ channel blocker, amlodipine (Amlod); (c) with T type Ca 2+ channel blocker, ML218; (d) with D2 receptor inhibitor, propionyl promazine (Propionyl); (e) with 5-HT 2A inhibitor, nefazodone (Nefaz). The layout is the same as in Figure 3

    Article Snippet: Moreover, the effects of asenapine on (Ca2+) c were abolished by H89, U73122, amlodipine, ML218, propionyl promazine, nefazodone, and L-NAME and reduced by KN93 [Figures , – and – ].

    Techniques:

    Effects of asenapine on cytosolic Ca 2+ in H9C2 in peroxidative conditions. (a) Dose-response and time-course study. The results are the mean ± standard deviation of five experiments. (b) An example taken from one experiment. (c) Effects of asenapine on Ca 2+ in the presence or absence of various blockers. C = Basal; A = Asenapine; Nefaz = Nefazodone (1 μM); propionyl = Propionyl promazine (1 μM); NAD = NAD-299 (1 μM); amlodip = Amlodipine (1 μM); ML218 = ML218 (1 μM); L-NAME = Nω-nitro-L-arginine methyl ester (10 mM). The results are the mean ± standard deviation of five experiments for each experimental protocol. (c) b, d, e P

    Journal: Journal of Pharmacology & Pharmacotherapeutics

    Article Title: Asenapine modulates nitric oxide release and calcium movements in cardiomyoblasts

    doi: 10.4103/0976-500X.179358

    Figure Lengend Snippet: Effects of asenapine on cytosolic Ca 2+ in H9C2 in peroxidative conditions. (a) Dose-response and time-course study. The results are the mean ± standard deviation of five experiments. (b) An example taken from one experiment. (c) Effects of asenapine on Ca 2+ in the presence or absence of various blockers. C = Basal; A = Asenapine; Nefaz = Nefazodone (1 μM); propionyl = Propionyl promazine (1 μM); NAD = NAD-299 (1 μM); amlodip = Amlodipine (1 μM); ML218 = ML218 (1 μM); L-NAME = Nω-nitro-L-arginine methyl ester (10 mM). The results are the mean ± standard deviation of five experiments for each experimental protocol. (c) b, d, e P

    Article Snippet: Moreover, the effects of asenapine on (Ca2+) c were abolished by H89, U73122, amlodipine, ML218, propionyl promazine, nefazodone, and L-NAME and reduced by KN93 [Figures , – and – ].

    Techniques: Standard Deviation

    Effects of asenapine on nitric oxide release in H9C2. (a) Dose-response and time-course study. (b) Effects of 15 min asenapine (10 pM-100 μM) in peroxidative conditions. (c) Effects of 2 min asenapine (100 nM) in the presence or absence of various agents. A = Asenapine; amlodip = Amlodipine (1 μM); NAD = NAD-299 (1 μM); Nefaz = Nefazodone (1 μM); propionyl = Propionyl promazine (1 μM); ML218 = ML218 (1 μM); 2'5' =2'5' dideoxyadenosine (1 μM): H89 = H89 (1 μM); KN93 = KN93 (1 μM); U73 = U73122 (1 μM); L-NAME = Nω-nitro-L-arginine methyl ester (10 mM). Nitric oxide release is expressed as % in comparison to basal values (c). The results are the mean ± standard deviation of five experiments for each experimental protocol. (c) b, c, e, g, i, m, o, q, s, u, z P

    Journal: Journal of Pharmacology & Pharmacotherapeutics

    Article Title: Asenapine modulates nitric oxide release and calcium movements in cardiomyoblasts

    doi: 10.4103/0976-500X.179358

    Figure Lengend Snippet: Effects of asenapine on nitric oxide release in H9C2. (a) Dose-response and time-course study. (b) Effects of 15 min asenapine (10 pM-100 μM) in peroxidative conditions. (c) Effects of 2 min asenapine (100 nM) in the presence or absence of various agents. A = Asenapine; amlodip = Amlodipine (1 μM); NAD = NAD-299 (1 μM); Nefaz = Nefazodone (1 μM); propionyl = Propionyl promazine (1 μM); ML218 = ML218 (1 μM); 2'5' =2'5' dideoxyadenosine (1 μM): H89 = H89 (1 μM); KN93 = KN93 (1 μM); U73 = U73122 (1 μM); L-NAME = Nω-nitro-L-arginine methyl ester (10 mM). Nitric oxide release is expressed as % in comparison to basal values (c). The results are the mean ± standard deviation of five experiments for each experimental protocol. (c) b, c, e, g, i, m, o, q, s, u, z P

    Article Snippet: Moreover, the effects of asenapine on (Ca2+) c were abolished by H89, U73122, amlodipine, ML218, propionyl promazine, nefazodone, and L-NAME and reduced by KN93 [Figures , – and – ].

    Techniques: Standard Deviation